HER2 is positively expressed in CRC, and some studies have shown that trastuzumab and lapatinib, drugs targeting HER2, can inhibit tumor formation by increasing macrophage levels and phagocytosis, and by increasing the infiltration of immune cells, it exerts a therapeutic effect on CRC metastasis (83, 146, 150, 151). This evidence concerns the gene ERBB2 and neoplasm.